Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte

Executive Summary

US FDA questions Clarus product's long-term safety in briefing documents for Bone, Reproductive and Urologic Drugs Advisory Committee meeting.

Advertisement

Related Content

Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval
Jatenzo v. Tlando: Similar Issues Did Not Lead To Similar Votes
Oral Testosterone Therapies Face Clinical Practice Difficulties, Advisory Panels Suggest
Clarus' Jatenzo Suffers From Off-Label Concerns At US Advisory Committee
Lipocine Testosterone Therapy Faces Safety, Stopping Criteria Concerns At US FDA Advisory Cmte
US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products
Oral Testosterone Battle Looms As Lipocine's Tlando Joins Clarus' Jatenzo In US FDA Review Queue
User Fee Goal Dates
Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel